Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sb-773812. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.44 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.44 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sb-773812 SCHEMBL5471358 | 1.00 | REV1 (0.45) | REV1DRD2HTR2AHTR2CDRD3 | |
| Sb-773812 SCHEMBL4510111 | 1.00 | REV1 (0.45) | REV1DRD2HTR2AHTR2CDRD3 | |
| SCHEMBL4889865 | 0.93 | DRD2 (0.50) | REV1DRD2HTR2AHTR2CDRD3 | |
| Sb-773812 SCHEMBL3896727 | 0.93 | DRD2 (0.50) | REV1DRD2HTR2AHTR2CDRD3 | |
| Sb-773812 SCHEMBL29377490 | 0.93 | DRD2 (0.50) | REV1DRD2HTR2AHTR2CDRD3 | |
| Hydrochloric Acid SCHEMBL3897702 | 0.92 | DRD2 (0.49) | REV1DRD2HTR2AHTR2CDRD3 | |
| Sb-773812 SCHEMBL3893974 | 0.92 | DRD2 (0.49) | REV1DRD2HTR2AHTR2CDRD3 | |
| Sb-773812 SCHEMBL5456117 | 0.88 | MMP1 (0.45) | REV1DRD2HTR2AHTR2CDRD3 | |
| SCHEMBL3897281 | 0.84 | HRH3 (0.46) | REV1DRD2HTR2AHTR2CDRD3 | |
| SCHEMBL4510117 | 0.84 | GRIN2C (0.42) | DRD2HTR2AHTR2CDRD3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163475-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2009-06-25 | — | — | US | claimed |
| EP-1885699-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2008-02-13 | — | — | EP | claimed |
| US-20070275948-A1 | 7-[4-(4-Chlorobenzyloxy)Benzenesulfonyl]-8-Methoxy-3-Methyl-2,3,4,5-Tetrahydro-1h-3-Benzazepinium Maleate Or Tosylate As antipyschotics | GLAXO GROUP LIMITED (GB) | 2007-11-29 | — | — | US | claimed |
| WO-2006125622-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2006-11-30 | — | — | WO | claimed |
| US-20090163475-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163475-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| CN-101184735-A | Crystalline form of benzazepinium maleate derivative | GLAXO GROUP LTD (GB) | 2008-05-21 | — | — | CN | disclosed |
| EP-1885699-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2008-02-13 | — | — | EP | disclosed |
| EP-1885699-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2008-02-13 | — | — | EP | disclosed |
| US-20070275948-A1 | 7-[4-(4-Chlorobenzyloxy)Benzenesulfonyl]-8-Methoxy-3-Methyl-2,3,4,5-Tetrahydro-1h-3-Benzazepinium Maleate Or Tosylate As antipyschotics | GLAXO GROUP LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070275948-A1 | 7-[4-(4-Chlorobenzyloxy)Benzenesulfonyl]-8-Methoxy-3-Methyl-2,3,4,5-Tetrahydro-1h-3-Benzazepinium Maleate Or Tosylate As antipyschotics | GLAXO GROUP LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070225276-A1 | 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | US | disclosed |
| WO-2006125622-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006125622-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2006-11-30 | — | — | WO | disclosed |
| EP-1687005-A1 | 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | disclosed |
| EP-1687279-A1 | 7- [4-(4-CHLOROBENZYLOXY) BENZENESULFONYL]-8-METHOXY-3-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINIUM MALEATE OR TOSYLATE AS ANTIPSYCHOTICS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | disclosed |
| EP-1687279-A1 | 7- [4-(4-CHLOROBENZYLOXY) BENZENESULFONYL]-8-METHOXY-3-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINIUM MALEATE OR TOSYLATE AS ANTIPSYCHOTICS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051916-A1 | 7-[4-(4-CHLOROBENZYLOXY) BENZENESULFONYL]-8-METHOXY-3-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINIUM MALEATE OR TOSYLATE AS ANTIPSYCHOTICS | GLAXO GROUP LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051916-A1 | 7-[4-(4-CHLOROBENZYLOXY) BENZENESULFONYL]-8-METHOXY-3-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINIUM MALEATE OR TOSYLATE AS ANTIPSYCHOTICS | GLAXO GROUP LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051398-A1 | 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225276-A1 | 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents | HTR4, DRD4, SLC6A3 | DRD2 46/4885HTR2A 448/4885REV1 4306/4885 |
| US-20090163475-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | CYP3A5, GABRA5, SLC6A13 | DRD2 197/4885HTR2A 128/4885REV1 4849/4885 |
| US-20070275948-A1 | 7-[4-(4-Chlorobenzyloxy)Benzenesulfonyl]-8-Methoxy-3-Methyl-2,3,4,5-Tetrahydro-1h-3-Benzazepinium Maleate Or Tosylate As antipyschotics | TPMT, HTR4, HTR7 | DRD2 128/4885HTR2A 70/4885REV1 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.